Group 1 - Feilong Co., Ltd. received a project designation notification letter from a well-known domestic automobile brand, becoming a supplier for a water-side thermal management module, with expected sales revenue during the lifecycle meeting disclosure standards [1] - Hanchuan Intelligent's controlling shareholder received a warning letter from Jiangsu Securities Regulatory Bureau for failing to timely disclose a share pledge contract, which may affect the company's control and stock price [2] - Vanke A completed the redemption of the "20 Vanke 04" corporate bonds, with a redemption amount of 1.5 billion yuan and interest payment of 51.75 million yuan [3][4] Group 2 - China Shenhua reported a 4% year-on-year decline in coal sales volume for April, totaling 35.6 million tons, and a 3.9% decrease in commodity coal production [5] - Shaanxi Black Cat plans to increase capital by 600 million yuan for its wholly-owned subsidiary Xinjiang Black Cat Coal Industry to enhance its capital strength [6][7] - China National Aviation reported an 8.6% year-on-year increase in passenger turnover for April, with a 5.3% increase in passenger capacity [8][9] Group 3 - Huabei Pharmaceutical's subsidiary received approval for clinical trials of a recombinant tetanus vaccine, which is a new generation vaccine with better safety and immunogenicity [10] - China Chemical's subsidiary received a lawsuit notice related to a securities false statement liability dispute [11] - China Metallurgical Group reported a 24.9% year-on-year decline in new contract value for January to April, totaling 308.4 billion yuan [13] Group 4 - Zhongmei Energy reported a 5.8% year-on-year decline in commodity coal sales for April, totaling 21.1 million tons [14] - Huangma Technology announced a plan to reduce holdings of up to 6.26 million shares due to personal funding needs [15] - Aiyingshi proposed a cash dividend of 2.53 yuan per 10 shares for the fiscal year 2024 [16] Group 5 - Shengyi Technology's executives plan to reduce their holdings by a total of 1.49 million shares [17] - CanSino's inhaled tuberculosis vaccine received clinical trial approval in Indonesia [18] - Beidouxingtong completed the acquisition of 51% of Shenzhen Tianli Automotive Electronics Technology Co., Ltd. [19] Group 6 - Spring Airlines reported a 12.29% year-on-year increase in available capacity for April, with a total of 4.73 billion ton-kilometers [20] - Dongya Pharmaceutical's raw material drug received registration certification in South Korea [21] - Shandong Steel plans to establish a sales subsidiary with a registered capital of 20 million yuan [22] Group 7 - Caida Securities appointed Hu Hengsong as the executive vice president [23] - Aibulu's vice president resigned due to personal career planning [24] - *ST Jinguang's stock price surged amid a warning of delisting risk [25] Group 8 - Yunnan Energy Investment plans to implement a 600,000 tons/year salt production energy-saving and carbon reduction project with a total investment of 448 million yuan [27] - Hanyu Group's executives plan to reduce their holdings due to personal funding needs [28] - Jiangsu Boyun's shareholders plan to reduce their holdings by up to 971,300 shares [29] Group 9 - Hainan Airport signed a cooperation agreement with Harbin Institute of Technology (Shenzhen) to establish a joint laboratory [32] - Xiamen Tungsten New Energy plans to acquire 47% of Ganzhou Haopeng Technology Co., Ltd. [33] - Dongfang Materials announced a change in controlling shareholder due to judicial auction of shares [34] Group 10 - Jingyuan Environmental Protection's executives plan to reduce their holdings by a total of 1.176% of the company's shares [35] - China Pacific Insurance reported a 10.4% year-on-year increase in original insurance premium income for the first four months [36] - ST United is planning a major asset restructuring and has suspended trading [37] Group 11 - *ST Suwu's chairman received a notice of investigation for suspected information disclosure violations [39] - Huagong Technology's subsidiary plans to establish a joint venture [40] - Qibin Group terminated the purchase of 28.78% equity in its subsidiary [41] Group 12 - Huakang Clean signed a construction contract worth 143 million yuan with Dengfeng City General Hospital [42] - Kanghong Pharmaceutical received approval for clinical trials of a drug for postpartum depression [43] - Shengjing Micro plans to repurchase shares worth between 30 million and 50 million yuan [44] Group 13 - Shenghe Resources' subsidiary plans to acquire 100% of Peak Rare Earths Limited for 158 million Australian dollars [45] - Sinopec's controlling shareholder increased its stake by 302 million H-shares, amounting to HKD 1.232 billion [46] - Mingyang Circuit plans to repurchase shares worth between 15 million and 25 million yuan [47] Group 14 - China Oil Engineering's subsidiary won a project in Iraq worth approximately 11.538 billion yuan [48] - Chaojie Co., Ltd. announced the termination of a share transfer agreement [49]

Core Viewpoint - Kanghong Pharmaceutical is actively advancing its drug pipeline, focusing on innovative treatments and maintaining a strong market position in the ophthalmology sector, particularly with its anti-VEGF product, Conbercept [1][3]. Group 1: Drug Development and Clinical Trials - The company is conducting a review for Lifisert eye drops at the National Medical Products Administration [1]. - KH109 and KH110 are in Phase III clinical trials, with KH109 already having completed subject enrollment and KH110 still in the process [1]. - KH110 aims to provide an innovative Chinese medicine solution for Alzheimer's disease, potentially enhancing the company's competitiveness in this therapeutic area [2]. - The clinical research for anxiety disorders using KH109 is progressing steadily, with completion of Phase III enrollment expected by April 2025 [1][2]. Group 2: Market Performance and Strategy - The company anticipates double-digit growth for Shugan Jieyu capsules in 2024, outpacing the overall antidepressant market growth [1]. - Kanghong Pharmaceutical has successfully entered multiple national procurement lists for its chemical drugs, including the Shongling Xue Mai Kang capsule, which has been selected in 23 provinces [2]. - The company is committed to increasing R&D investments across innovative drugs, traditional Chinese medicine, and chemical generics to provide high-quality, cost-effective products [2]. Group 3: Competitive Landscape - Conbercept has established itself as a leader in the Chinese anti-VEGF market, competing against top global brands [3]. - The company has a successful track record of overcoming challenges in the market, demonstrating confidence in maintaining its competitive edge [3]. - The incidence rates for the five major indications of anti-VEGF products are stable, suggesting consistent market demand [3]. Group 4: Management and Operational Efficiency - The company plans to enhance internal control management and performance evaluation to improve overall management efficiency [4]. - There is a focus on advancing infrastructure projects for planned production and improving brand promotion and marketing management [4]. - Financial management will be strengthened, with an emphasis on cost control, budget execution, and monitoring of fund operations to mitigate financial risks [4].

Group 1: Clinical Trials and Research - KH631 and KH658 are currently in clinical trials, with safety and efficacy data not yet fully compiled [2] - KH631's clinical data is expected to be disclosed at the 2025 ARVO conference [2] - The company has a diverse R&D system covering traditional Chinese medicine, antibody drugs, gene therapy, and small molecule drugs [10] Group 2: Financial Performance and Projections - In 2024, the company achieved a revenue of CNY 4,452,657,799, a year-on-year increase of 12.51%, and a net profit of CNY 1,191,230,760.93, up 14.02% [14] - For 2025, the company projects a revenue growth of 5%-15% and a net profit growth of 5%-15% compared to 2024 [9] - R&D expenses in 2024 increased by 33.57% to CNY 604,378,287.33 [8] Group 3: Strategic Focus and Market Position - The core competitive advantage lies in strategic layout and continuous innovation across various product lines [3] - The company is focusing on enhancing internal control management and performance assessment to improve overall management efficiency [26] - The company maintains a strong market position in the anti-VEGF sector, with confidence in overcoming competition from global brands [6] Group 4: Product Development and Pipeline - Key products in clinical trials include KH631 for nAMD, KH658 for nAMD, and KH617 for advanced solid tumors [5] - The company is advancing the clinical trials of KH110 for Alzheimer's disease and KH109 for anxiety [15] - The company is actively responding to market competition and regulatory changes, particularly in the traditional Chinese medicine sector [8] Group 5: Future Outlook and Industry Trends - The pharmaceutical industry is viewed as a "perpetual sunrise industry" with significant growth potential [13] - The company is committed to increasing R&D investments to provide high-quality, cost-effective products [22] - The company is exploring international collaboration opportunities to enhance its global market presence [30]

药品名称：KH607 片 剂型：片剂 适应症：产后抑郁症 注册分类：化药 1 类 证券代码：002773 证券简称：康弘药业 公告编号：2025-021 成都康弘药业集团股份有限公司 关于公司收到药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 近日，成都康弘药业集团股份有限公司（以下简称"公司"）收 到国家药品监督管理局签发的《药物临床试验批准通知书》。现将相 关情况公告如下： 一、药品基本信息 1 / 2 三、对公司的影响 由于药品从研发、临床试验、审评和审批的结果以及时间都具有 一定的不确定性，敬请广大投资者谨慎决策，注意投资风险。 特此公告。 成都康弘药业集团股份有限公司董事会 2025 年 5 月 14 日 2 / 2 受理号：CXHL2500223、CXHL2500224 审批结论：同意开展治疗产后抑郁症的临床试验 二、产品简介 KH607 是我公司自主研发的小分子 γ-氨基丁酸 A 亚型（GABAA） 受体正向变构调节剂，属于化药 1 类创新药，剂型为口服固体制剂片 剂,2023 年已获批同意开展治疗抑郁症的临床试验。 ...

Core Viewpoint - Kanghong Pharmaceutical has experienced a decline in stock price over four consecutive trading days, with a cumulative drop of 8.09% [1] Company Overview - Chengdu Kanghong Pharmaceutical Group Co., Ltd. was established in 1996 and focuses on the research, production, sales, and after-sales service of biological products, traditional Chinese medicine, chemical drugs, and medical devices [1] - The company possesses advanced research and development centers and standardized industrial production bases, with a marketing network that spans the entire country [1] Shareholder Activity - Three funds under Dacheng Fund have entered the top ten shareholders of Kanghong Pharmaceutical, including: - Dacheng Strategy Return Mixed A, which increased its holdings in Q1 of this year - Dacheng Competitive Advantage Mixed A, which also increased its holdings in Q1 - Dacheng Rui Xiang Mixed A, which entered as a new shareholder in Q1 [1] - The performance of these funds in 2023 is as follows: - Dacheng Strategy Return Mixed A: 1.46% return, ranking 2872 out of 4548 - Dacheng Competitive Advantage Mixed A: 4.62% return, ranking 1825 out of 4548 - Dacheng Rui Xiang Mixed A: 2.35% return, ranking 2545 out of 4548 [1] Fund Management - The fund manager for Dacheng Strategy Return Mixed A, Dacheng Competitive Advantage Mixed A, and Dacheng Rui Xiang Mixed A is Xu Yan [5][7] - Xu Yan holds a master's degree in management from Fudan University and has extensive experience in fund management, having worked at Dacheng Fund Management Co., Ltd. since 2007 [6]

为充分尊重投资者，提升交流的针对性，现就公司二〇二四年度 业绩网上说明会提前向投资者公开征集问题，广泛听取投资者的意见 和 建 议 。 投 资 者 可 于 2025 年 5 月 14 日 （ 星 期 三 ） 16 ： 00 前 访 问 https://ir.p5w.net/zj/，进入问题征集专题页面进行提问。公司将 在本次年度业绩说明会上对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次业绩说明会。 特此公告。 证券代码：002773 证券简称：康弘药业 公告编号：2025-020 成都康弘药业集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"康弘药业"、"公 司"）《2024年年度报告》《2024年年度报告摘要》已于2025年4月 发展规划，公司将于2025年5月15日（星期四）下午15：00至17：00 在全景网举行康弘药业二〇二四年度网上业绩说明会，本次说明会将 采用网络远程方式举行，投资者可登录全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次业绩说明会。 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"康弘药业"、"公 司"）《2024年年度报告》《2024年年度报告摘要》已于2025年4月 26日披露。为使投资者进一步了解公司的财务状况、经营情况及公司 发展规划，公司将于2025年5月15日（星期四）下午15：00至17：00 在全景网举行康弘药业二〇二四年度网上业绩说明会，本次说明会将 采用网络远程方式举行，投资者可登录全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次业绩说明会。 证券代码：002773 证券简称：康弘药业 公告编号：2025-020 成都康弘药业集团股份有限公司 关于举行二〇二四年度网上业绩说明会的公告 出席本次业绩说明会的人员有：公司董事长柯尊洪先生，董事、 总裁柯潇先生，董事、副总裁钟建荣女士、殷劲群先生，独立董事周 德敏先生、邓宏光先生、许楠女士，副总裁、财务总监钟建军先生， 副总裁徐燕华女士，董事会秘书邓康先生。 为充分尊重投资者，提升交流的针对性，现就公司二〇二四年度 业绩网上说明会提前向投资者公开征集问题，广 ...

近日，公司已向中国证券登记结算有限责任公司深圳分公司提交 注销上述股票期权的申请，截至本公告披露日，经中国证券登记结算 有限责任公司深圳分公司审核确认，公司已完成上述 198,750 份股票 期权的注销业务。前述注销 2021 年股票期权激励计划部分股票期权 事项符合《上市公司股权激励管理办法》及公司《2021 年股票期权激 证券代码：002773 证券简称：康弘药业 公告编号：2025-019 成都康弘药业集团股份有限公司 关于2021年股票期权激励计划部分股票期权 注销完成的公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 成都康弘药业集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第八届董事会第十次会议和第八届监事会第十次会议， 审议通过了《关于注销 2021 年股票期权激励计划部分股票期权的议 案》。根据公司《2021 年股票期权激励计划（草案）》的相关规定，由 于 2021 年股票期权激励计划首次授予部分的 13 名激励对象离职，董 事会根据公司二〇二一年第一次临时股东大会的授权，决定注销 ...

Group 1: Shanghai Jahwa - Shanghai Jahwa is confident about achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The employee stock ownership plan aims to enhance competitiveness, reduce turnover, and foster a sense of ownership among employees [1] - The company has made strategic adjustments in the past six months, including organizational design, talent development, and cultural initiatives [1] - E-commerce strategies include inventory optimization, pricing adjustments, organizational restructuring, and product iteration [1] - The company targets double-digit revenue growth this year and aims to turn profits around [1] - Long-term profit recovery is expected to follow a 1-2 year revenue growth, 2-3 year profit improvement, and 3-5 year profit margin targets [1] Group 2: Zhuoyi Information - Zhuoyi Information has approximately 7,000 active users for its SnapDevelop platform and plans to release a paid commercial version [2] - EazyDevelop, which focuses on rapid development using AI technology, will have a free trial version available after development [2] - The company has made breakthroughs in RISC-V firmware and is collaborating with major firms like Huawei and Lenovo [2] Group 3: Chipbond Technology - Chipbond Technology has made progress in advanced packaging, with its WLP2000 equipment entering mass production preparation after client validation [3] - The company benefits from advantageous direct-write lithography technology and has seen a 22.31% year-on-year increase in revenue and a 30.45% increase in net profit in Q1 [3] - The company expects overseas orders to account for nearly 20% by 2024, indicating strong international market competitiveness [3] Group 4: Kanghong Pharmaceutical - Kanghong Pharmaceutical's KPB-101 has established a leading position in China's ophthalmic anti-VEGF market and aims for further achievements [4] - The company focuses on diverse research and development in ophthalmology, neurology, and oncology, with a strong emphasis on innovative drug sales [4] - The company anticipates a revenue and net profit growth of 5%-15% year-on-year by 2025, with specific products expected to see significant sales growth [4]

Market Position and Growth Potential - Kanghong Pharmaceutical has established a leading position in the Chinese ophthalmic anti-VEGF market, competing against three major global brands [2] - The company has successfully navigated market challenges over the past decade, demonstrating confidence in continuing to outperform international competitors [2] - The incidence rates of the five major indications for anti-VEGF products are stable, suggesting that Kanghong's growth will align with the overall market trend [2] Research and Development Strategy - The company focuses on key therapeutic areas: ophthalmology, psychiatry/neuroscience, and oncology, with a diversified R&D system covering traditional Chinese medicine, antibody drugs, gene therapy (AAV), and small molecule drugs [3] - Kanghong is advancing multiple innovative projects, including the "Shu Gan Jie Yu Capsule" for anxiety disorders, which is currently in phase III clinical trials [3][7] - The company plans to disclose clinical data for its gene therapy products through international academic journals and conferences [4] Financial Outlook - For 2025, Kanghong anticipates a revenue growth of 5%-15% compared to 2024, with a similar net profit growth forecast [7] - The "Shu Gan Jie Yu Capsule" is expected to see double-digit growth in 2024, outpacing the overall antidepressant market [7] Competitive Landscape and Policy Impact - The competitive landscape for anti-VEGF products has intensified, with four innovative drugs and two biosimilars entering the market following successful negotiations with national health insurance [5] - Kanghong is adapting to national procurement policies, with a significant portion of its chemical drugs selected for national procurement [4] Talent and Collaboration - The company emphasizes talent acquisition and development to support its R&D needs, particularly in gene therapy and advanced drug delivery systems [6] - External collaborations are viewed as a core strategy for long-term value growth, focusing on complementary technologies and commercial synergies [6]